The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Open accessAbstract
BACKGROUND: Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. METHODS: We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes. RESULTS: Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval [CI], 1.03 to 1.98; P=0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P=0.06). CONCLUSIONS: Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although our analysis is secondary, reanalyses of clinical trial data have led to the detection of adverse events well after the market entry of major drugs such as rofecoxib and rosiglitazone. [36,37]”
From Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults (2022) · cites this paper as [37]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In one study, 9 the use of rosiglitazone decreased the risk of diabetes in adults with impaired glucose tolerance by 62%; given concerns about cardiovascular safety, 14 however, the Food and Drug Administration has restricted the use of rosig litazone therapy to patients in whom glycemic control cannot be achieved with other medications and who cannot take pioglitazone.”
From Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“a well-publicized meta-analysis of small phase 3 trials suggesting an increase in myocardial ischemic events (odds ratio, 1.43 [95% CI, 1.03–1.98])”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [210]
In the citing paper
“Several meta-analyses have suggested a 30–40% relative increase in risk for myocardial infarction (65,66) with rosiglitazone.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 831
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 790
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Nissen, S. E. (2005) · JAMA · doi:10.1001/jama.294.20.joc50147 · Cited by 552
Self-citationEffect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus
Fonseca, V. A., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 538
Research works printed but not linked: 1
- 10.1210/jc.86.1.280 · DOI
Cited by
Sorted by citations
Items 701–800 of 1,024
Pharmacologic management of the older patient with type 2 diabetes mellitus
Neumiller, J. J., & Setter, S. M. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.12.002 · Cited by 78
Jauregui, A. N., Mintz, D. H., Mundel, P. H., & Fornoni, A. (2009) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32832f7002 · Cited by 76
Mitochondria and heart failure
Murray, A. J., Edwards, L. M., & Clarke, K. (2007) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3282f0ecbe · Cited by 76
Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli, A., & Formoso, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12101 · Cited by 76
PPARγ Activation: A Potential Treatment For Pulmonary Hypertension
Hansmann, G., & Zamanian, R. T. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000267 · Cited by 76
Inflammation and lung carcinogenesis: applying findings in prevention and treatment
Peebles, K. A., Lee, J. M., Mao, J. T., Hazra, S., Reckamp, K. L., Krysan, K., Dohadwala, M., Heinrich, E. L., Walser, T. C., Cui, X., et al. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.10.1405 · Cited by 77
Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone
Shah, N. D., Montori, V. M., Krumholz, H. M., Tu, K., Alexander, G. C., & Jackevicius, C. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1011042 · Cited by 76
Hedin, R. J., Umberham, B. A., Detweiler, B., Kollmorgen, L., & Vassar, M. B. (2016) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000001452 · Cited by 81
Zeng, X., Wang, Y., Cantley, J., Iseli, T. J., Molero, J. C., Hegarty, B. D., Kraegen, E. W., Yang, Y., & Ye, J.-M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042115 · Cited by 78
Cardiovascular Function in Nonclinical Drug Safety Assessment
Sarazan, R. D., Mittelstadt, S. W., Guth, B. D., Koerner, J. E., Zhang, J., & Pettit, S. D. (2011) · International Journal of Toxicology · doi:10.1177/1091581811398963 · Cited by 75
Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease
Yoon, H. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i11.800 · Cited by 75
Examining the safety of PPAR agonists – current trends and future prospects
Bortolini, M., Wright, M. B., Bopst, M., & Balas, B. I. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.741585 · Cited by 76
Exact Meta-Analysis Approach for Discrete Data and its Application to 2 × 2 Tables With Rare Events
Liu, D., Liu, R. Y., & Xie, M. (2014) · Journal of the American Statistical Association · doi:10.1080/01621459.2014.946318 · Cited by 75
Miranda, C. L., Johnson, L. A., de Montgolfier, O., Elias, V. D., Ullrich, L. S., Hay, J. J., Paraiso, I. L., Choi, J., Reed, R. L., Revel, J. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18992-6 · Cited by 75
Trachtman, H., Vento, S., Herreshoff, E. G., Radeva, M., Gassman, J., Stein, D. T., Savin, V. J., Sharma, M., Reiser, J., Wei, C., et al. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0094-5 · Cited by 74
Current perspectives on cardiovascular outcome trials in diabetes
on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0456-8 · Cited by 73
Dual PPARα/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction
Kalliora, C., Kyriazis, I. D., Oka, S., Lieu, M., Yue, Y., Área-Gómez, E., Pol, C. J., Tian, Y., Mizushima, W., Chin, A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129556 · Cited by 77
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
Bae, J., Park, T., Kim, H., Lee, M., & Soo, B. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0272 · Cited by 79
Niacin: a re‐emerging pharmaceutical for the treatment of dyslipidaemia
Vosper, H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00349.x · Cited by 75
Fraulob, J. C., Souza‐Mello, V., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2012) · Clinical Science · doi:10.1042/cs20110373 · Cited by 76
Peroxisome proliferator-activated receptors and the metabolic syndrome
Bragt, M. C. E., & Popeijus, H. E. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.053 · Cited by 73
Solini, A., Penno, G., Bonora, E., Fondelli, C., Orsi, E., Trevisan, R., Vedovato, M., Cavalot, F. L., Cignarelli, M., Morano, S., et al. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12381 · Cited by 74
Hirshberg, B., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s202 · Cited by 73
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan, D., Clar, C., Ghouri, N., Henderson, R., Gurung, T. M., Preiss, D., Sattar, N. A., Fraser, A., & Waugh, N. R. (2011) · Health Technology Assessment · doi:10.3310/hta15380 · Cited by 76
Labreuche, J., Deplanque, D., Touboul, P., Bruckert, É., & Amarenco, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.02.011 · Cited by 75
Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus
Derosa, G. (2010) · Drugs · doi:10.2165/11538100-000000000-00000 · Cited by 75
Yang, Y., Qiu, W., Xiao, J., Sun, J., Ren, X., & Jiang, L. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05060-7 · Cited by 77
Microvascular responsiveness in obesity: implications for therapeutic intervention
Bagi, Z. A., Fehér, A., & Cassuto, J. R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01606.x · Cited by 69
Boggild, A. K., Krudsood, S., Patel, S. N., Serghides, L., Tangpukdee, N., Katz, K. C., Wilairatana, P., Liles, W. C., Looareesuwan, S., & Kain, K. C. (2009) · Clinical Infectious Diseases · doi:10.1086/605431 · Cited by 73
Li, Y., Kovach, A., Suino-Powell, K. M., Martynowski, D., & Xu, H. E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802040200 · Cited by 75
Emerging therapies for chronic kidney disease: what is their role?
Vilayur, E., & Harris, D. C. H. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.76 · Cited by 73
Cardiovascular Disease in Diabetes Mellitus
Szuszkiewicz-Garcia, M., & Davidson, J. A. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.001 · Cited by 76
Dong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71
Little, P. J., Chait, A., & Bobik, A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.04.001 · Cited by 73
Beaudoin, M., Snook, L. A., Arkell, A. M., Simpson, J. A., Holloway, G. P., & Wright, D. C. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00200.2013 · Cited by 73
Kongwatcharapong, J., Dilokthornsakul, P., Nathisuwan, S., Phrommintikul, A., & Chaiyakunapruk, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.146 · Cited by 72
Cardiac safety profile of rosiglitazone
Mannucci, E., Monami, M., Bari, M. D., Lamanna, C., Gori, F., Gensini, G. F., & Marchionni, N. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.01.064 · Cited by 72
Emerging treatment options for type 2 diabetes
Piya, M. K., Tahrani, A. A., & Barnett, A. H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03711.x · Cited by 73
Berneis, K. K., Rizzo, M., Stettler, C., Chappuis, B., Braun, M., Diem, P., & Christ, E. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.3.343 · Cited by 72
Perfect Study, Poor Evidence: Interpretation of Biases Preceding Study Design
Ioannidis, J. P. A. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.04.010 · Cited by 72
Higgins, S. J., Kain, K. C., & Liles, W. C. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.96 · Cited by 72
Diabetic cardiomyopathy – a distinct disease?
Khavandi, K., Khavandi, A., Asghar, O., Greenstein, A. S., Withers, S., Heagerty, A. M., & Malik, R. A. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.016 · Cited by 72
Identifying plausible adverse drug reactions using knowledge extracted from the literature
Shang, N., Xu, H., Rindflesch, T. C., & Cohen, T. (2014) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2014.07.011 · Cited by 75
Ibrahim, M. K., Eissa, I. H., Abdallah, A. E., Metwaly, A. M., Radwan, M. M., & ElSohly, M. A. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.01.015 · Cited by 74
Levelt, E., Gulsin, G. S., Neubauer, S., & McCann, G. P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0724 · Cited by 76
No news is good news: voluntary disclosure in the face of litigation
Marinovic, I., & Varas, F. (2016) · The RAND Journal of Economics · doi:10.1111/1756-2171.12156 · Cited by 72
Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal
Scheen, A. J., & Charbonnel, B. H. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.03.004 · Cited by 71
Association of Fetuin-A With Incident Diabetes Mellitus in Community-Living Older Adults
Ix, J. H., Biggs, M. L., Mukamal, K. J., Kizer, J. R., Zieman, S. J., Siscovick, D. S., Mozaffarian, D., Jensen, M. K., Nelson, L., Ruderman, N. B., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.072751 · Cited by 71
GLP-1–Based Therapy for Diabetes: What You Do Not Know Can Hurt You
Butler, P. C., Dry, S., & Elashoff, R. M. (2010) · Diabetes Care · doi:10.2337/dc09-1902 · Cited by 69
Ou, H., Chang, K., Li, C., & Wu, J. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0350-4 · Cited by 72
The current role of thiazolidinediones in diabetes management
Rizos, C. V., Kei, A. A., & Elisaf, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1737-4 · Cited by 71
Mitochondria and Redox Signaling in Steatohepatitis
Morris, E. M., Rector, R. S., Thyfault, J. P., & Ibdah, J. A. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3795 · Cited by 71
Lombardi, A., Cantini, G., Piscitelli, E., Gelmini, S., Francalanci, M., Mello, T., Ceni, E., Varano, G., Forti, G., Rotondi, M., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.160713 · Cited by 71
Nonalcoholic fatty liver disease as a component of the metabolic syndrome
Khashab, M. A., Liangpunsakul, S., & Chalasani, N. (2008) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0012-0 · Cited by 71
Huard, K., Brown, J. A., Jones, J. E. C., Cabral, S., Futatsugi, K., Gorgoglione, M. F., Lanba, A., Vera, N. B., Zhu, Y., Yan, Q., et al. (2015) · Scientific Reports · doi:10.1038/srep17391 · Cited by 71
ubowska, J. K., Malaguarnera, L., Wąż, P., & Zorena, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160614095559 · Cited by 71
Flavonoids as Putative Inducers of the Transcription Factors Nrf2, FoxO, and PPARγ
Pallauf, K., Duckstein, N., Hasler, M., Klotz, L., & Rimbach, G. H. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/4397340 · Cited by 71
Okine, B. N., Gaspar, J. C., & Finn, D. P. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14339 · Cited by 70
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 71
Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management
Khunti, K., Zaccardi, F., Amod, A., Aroda, V. R., Montoya, P. A., Colagiuri, S., Mohan, V., & Chan, J. C. N. (2024) · Diabetologia · doi:10.1007/s00125-024-06254-w · Cited by 78
Vascular dysfunction in cerebrovascular disease: mechanisms and therapeutic intervention
Miller, A. A., Budzyn, K., & Sobey, C. G. (2010) · Clinical Science · doi:10.1042/cs20090649 · Cited by 71
Recent advances in the management of type 2 diabetes mellitus: a review
Srinivasan, B. T., Jarvis, J., Khunti, K., & Davies, M. J. (2008) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.067918 · Cited by 70
Rosiglitazone Is Associated with Mortality in Chronic Hemodialysis Patients
Ramirez, S. P. B., Albert, J. M., Blayney, M. J., Tentori, F., Goodkin, D. A., Wolfe, R. A., Young, E. W., Bailie, G. R., Pisoni, R. L., & Port, F. K. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008060579 · Cited by 69
Forecasting drug utilization and expenditure in a metropolitan health region
Wettermark, B., Persson, M. E., Wilking, N. E., Kalin, M., Korkmaz, S., Hjemdahl, P., Godman, B., Petzold, M., & Gustafsson, L. L. (2010) · BMC Health Services Research · doi:10.1186/1472-6963-10-128 · Cited by 70
The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes
Amod, A. (2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872276 · Cited by 69
Update on diabetes in the elderly and in nursing home residents
Migdal, A., Yarandi, S. S., Smiley, D., & Umpierrez, G. E. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.02.010 · Cited by 81
Nonalcoholic Fatty Liver Disease and the Coronary Artery Disease
Treeprasertsuk, S., López-Jiménez, F. A., & Lindor, K. D. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1241-2 · Cited by 70
Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2
Maranta, F., Cianfanelli, L., & Cianflone, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_514 · Cited by 74
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
Salvatore, T., Caturano, A., Galiero, R., Martino, A. D., Albanese, G., Vetrano, E., Sardu, C., Marfella, R., Rinaldi, L., & Sasso, F. C. (2021) · Biomedicines · doi:10.3390/biomedicines9101356 · Cited by 72
Rosiglitazone: a European regulatory perspective
BLIND, E., Dunder, K., de Graeff, P. A., & Abadie, E. (2010) · Diabetologia · doi:10.1007/s00125-010-1992-5 · Cited by 70
Vestigial-like 3 is an inhibitor of adipocyte differentiation
Halperin, D. S., Pan, C., Lusis, A. J., & Tontonoz, P. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m032755 · Cited by 69
Cardiotoxicity screening: a review of rapid-throughput in vitro approaches
Li, X., Zhang, R., Zhao, B., Lossin, C., & Cao, Z. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1651-1 · Cited by 70
Lu, C.-H., Yang, C., Li, C., Hsieh, C., & Ou, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4499-5 · Cited by 70
Hansen, R. A., Farley, J. F., Droege, M., & Maciejewski, M. L. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.07.011 · Cited by 68
Li, X.-J., Yu, Y.-X., Liu, C.-Q., Zhang, W., Zhang, H.-J., Yan, B., Wang, L.-Y., Yang, S.-Y., & Zhang, S.-H. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03917.x · Cited by 67
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
Brownstein, J. S., Sordo, M., Kohane, I. S., & Mandl, K. D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000840 · Cited by 69
Hirsch, L. J. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.9.811 · Cited by 67
Michos, E. D., Sibley, C. T., Baer, J., Blaha, M. J., & Blumenthal, R. S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.045 · Cited by 68
Hemodynamic Effects of Glucagon: A Literature Review
Petersen, K. M., Bøgevig, S., Holst, J. J., Knop, F. K., & Christensen, M. B. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00050 · Cited by 68
Consensus on the key characteristics of metabolism disruptors
Merrill, M. A. L., Smith, M. T., McHale, C. M., Heindel, J. J., Atlas, E., Cave, M. C., Collier, D. N., Guyton, K. Z., Koliwad, S. K., Nadal, Á., et al. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01059-8 · Cited by 73
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Saisho, Y. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030923 · Cited by 75
Rao, Y. K., Lee, M., Chen, K., Lee, Y., Wu, W., & Tzeng, Y. (2009) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nep204 · Cited by 68
Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
Bergenstal, R. M., Bailey, C. J., & Kendall, D. M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.07.017 · Cited by 70
Nonalcoholic Fatty Liver Disease
Paredes, A. H., Torres, D. M., & Harrison, S. A. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.005 · Cited by 72
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
Wilding, J. P. H. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01601.x · Cited by 71
PPARs as therapeutic targets in cardiovascular disease
van Bilsen, M., & van Nieuwenhoven, F. A. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.512917 · Cited by 67
Dawed, A. Y., Donnelly, L. A., Tavendale, R., Carr, F., Leese, G., Palmer, C. N. A., Pearson, E. R., & Zhou, K. (2016) · Diabetes Care · doi:10.2337/dc15-2464 · Cited by 68
Mahajan, U. B., Chandrayan, G., Patil, C. R., Arya, D. S., Suchal, K., Agrawal, Y. O., Ojha, S. K., & Goyal, S. N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040756 · Cited by 68
Nonalcoholic fatty liver disease in A sia: A story of growth
Wong, V. W. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12011 · Cited by 69
The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
Friedland, S. N., Leong, A., Filion, K. B., Genest, J. J., Lega, I. C., Mottillo, S., Poirier, P., Reoch, J., & Eisenberg, M. J. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.025 · Cited by 67
Heppner, K. M., & Tong, J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0183 · Cited by 68
Rosenson, R. S., Wright, R. S., Farkouh, M. E., & Plutzky, J. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.06.023 · Cited by 67
Saleem, F., Kanwal, Khan, K. M., Chigurupati, S., Solangi, M., Nemala, A. R., Mushtaq, M., Ul‐Haq, Z., Taha, M., & Perveen, S. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104489 · Cited by 67
Hussain, R., Iqbal, S., Shah, M., Rehman, W. U., Khan, S., Rasheed, L., Rahim, F., Dera, A. A., Kehili, S., Elkaeed, E. B., et al. (2022) · Molecules · doi:10.3390/molecules27196457 · Cited by 69
Kamata, S., Honda, A., & Ishii, I. (2023) · Biomolecules · doi:10.3390/biom13081264 · Cited by 71
Endothelial Dysfunction in Obesity and Therapeutic Targets
Engin, A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-63657-8_17 · Cited by 78
Pedersen, G., & Brynskov, J. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.749 · Cited by 67
An exercise intervention to improve diabetic patients’ gait in a real-life environment
Allet, L., Armand, S., Aminian, K., Pataky, Z., Golay, A., de Bie, R. A., & de Bruin, E. D. (2010) · Gait & Posture · doi:10.1016/j.gaitpost.2010.04.013 · Cited by 67
Study on the hypoglycemic activities and metabolism of alcohol extract of Alismatis Rhizoma
Li, Q., & Qu, H. (2012) · Fitoterapia · doi:10.1016/j.fitote.2012.05.009 · Cited by 67
Metadata
- Authors
- Nissen, S. E., & Wolski, K.
- Affiliations
- Cleveland Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2457-2471
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127125241
- Semantic Scholar
- 238422dc26dc6a78cb2b03fad835d7d1f1f95edb
- Cited by
- 4,675
- References
- 29
- Citations by year
- 2026: 62 · 2025: 66 · 2024: 89 · 2023: 117 · 2022: 132 · 2021: 169 · 2020: 175 · 2019: 198 · 2018: 213 · 2017: 222 · 2016: 234 · 2015: 218 · 2014: 259 · 2013: 271 · 2012: 295
- FWCI
- 395.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- New England Journal of Medicine (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- rosiglitazone, myocardial infarction, cardiovascular mortality, type 2 diabetes, thiazolidinediones, drug safety, HbA1c
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Middle Aged, Myocardial Infarction, Odds Ratio, Randomized Controlled Trials as Topic, Risk Assessment, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
